INSIGHTS ON DRUG DEVELOPMENT
-
![doctor holding vial of medicine-GettyImages-1287223643]( "A Patented Process For Intermediates Useful For Upadacitinib")
A Patented Process For Intermediates Useful For UpadacitinibDiscover how innovative and safer synthetic strategies can streamline the manufacture of Upadacitinib while addressing the complexity and safety challenges inherent in its key intermediates.
-
![IDBS Polar]( "Scientific Data Is Not AI‑Ready By Default")
Scientific Data Is Not AI‑Ready By DefaultConvert siloed laboratory data into trusted, AI-ready assets. Learn to enforce data integrity principles at the point of origin to streamline analytics and reduce GxP compliance risks.
-
![GettyImages-2199680273-lab-computer-scientist-in-lab-coat]( "How Automation Helps Life Sciences Manufacturers Deliver Faster, Safer Therapies")
How Automation Helps Life Sciences Manufacturers Deliver Faster, Safer TherapiesAutomation paired with smart data management is becoming the base for faster drug and vaccine production without trading away quality. Five investment priorities show where manufacturers are concentrating their efforts.
-
![Mark Benger]( "Ask Us Anything: Mark Benger On Solid-State Strategies For Drug Development")
Ask Us Anything: Mark Benger On Solid-State Strategies For Drug DevelopmentMark Benger, Site Director at Cambrex Edinburgh, on solid-state characterization as an insurance policy — front-loaded work that quietly determines whether a program survives the jump from kilos to tonnes.
-
Three Keys To E&L Success: Study Design, Partner Selection, And Timing7/16/2026
Successful E&L planning starts before testing begins. Aligning study design, partner expertise, and timing helps teams focus on the right risks, avoid surprises, and support stronger development.
-
Differentiate Challenging Site-Specific Isomeric Amino Acids8/24/2026
Learn how high-resolution ion mobility, pre-IMS fragmentation, and product ion analysis can resolve difficult peptide isomers and localize structural differences, supporting confident characterization.
-
5 Hidden Risks In Early-Phase OSD Formulation Development8/31/2026
Early formulation decisions in OSD development carry risks that may not surface until later stages, when the cost of course correction is significantly higher.
-
Turning A "Brick Dust" Compound Into A Clinically Viable Oral Formulation11/2/2026
Advanced wet milling and particle stabilization improve solubility, enhance bioavailability, and support scalable manufacturing for complex oral drug development programs.
-
Versatile Lipid Nanoparticle Platform For Efficient Gene Editing6/3/2025
Lipid nanoparticles enable efficient gene editing in hard-to-transfect cells like T-cells and blood stem cells, which offers scalable, clinically relevant methods for developing advanced therapies for cancer and rare diseases.
DRUG DEVELOPMENT SOLUTIONS
-
![GettyImages-1268717577-doctor-meeting-with-business-professional-computer-office]( "Accelerating FIH Trials To POC With Speed, Safety, And Certainty")
Overcome clinical transition challenges with integrated services, including study design, expert regulatory support, robust recruitment, and flexible manufacturing.
-
![Nasal Dosage Form Development]( "Nasal Dosage Form Development")
Upperton have developed UpperNose™, a nasal product development approach designed to streamline the development process for nasal dosage forms.
-
![leica-microsystems-stellaris-8-falcon-hero]( "Lifetime Imaging In An Instant With A FLIM Microscope")
STELLARIS 8 FALCON FLIM Microscope
The contrast is clear. Lifetime imaging in an instant.
STELLARIS 8 FALCON (FAst Lifetime CONtrast) is the future of functional imaging. Harness the power of fluorescence lifetime to investigate cellular physiology and explore dynamics in living cells. STELLARIS 8 FALCON is a fully integrated solution for Fluorescence Lifetime Imaging (FLIM) and enables video-rate lifetime imaging acquisition for rapid kinetic studies in live cells.
STELLARIS 8 FALCON adds a new dimension of contrast to your imaging, opening the door to biosensing and tracking of interactions between proteins. FLIM information is now available for all modalities of the STELLARIS 8 system.
-
![Female researcher analyzing scientific samples-GettyImages-2231025177]( "Advance Your Lead Oligonucleotide Candidates From Discovery To Market")
Synthetic oligonucleotide therapeutics, such as antisense oligonucleotides (ASOs) and small interfering RNAs (si-RNAs), require thorough analysis to establish purity and quality.
-
![GettyImages-1166528597-scientist-lab-equipment-tubing]( "Accelerate Drug Development With Reliable Pharmaceutical Research")
Tailored support is available for diverse molecules, including small and large molecules, nucleic acid therapies, and novel delivery systems. Services span drug substance to regulatory affairs.
